[0005] DGAT2 is an integral membrane protein of the endoplasmic reticulum and is expressed strongly in adipose tissue and the liver. DGAT2 appears to be the dominant DGAT enzyme controlling TG homeostasis *in vivo*. DGAT2 deficient mice survive for only a few hours after birth. On the other hand, DGAT1 deficient mice are viable (Yen *et al.*, *J. Lipid Research*, 2008, 49, 2283).


[0006] Despite this perinatal lethal phenotype, the metabolic role of DGAT2 has been mostly comprehended from effort exploiting anti-sense oligonucleotides (ASO) in rodents. In this setting, DGAT2 knockdown in *ob/ob* mice with a DGAT2 gene-specific ASO resulted in a dose dependent decrease in very low density lipoprotein ("VLDL") and a reduction in plasma TG, total cholesterol, and ApoB (Liu, *et al.*, *Biochim. Biophys Acta* 2008, 1781, 97). In the same study, DGAT2 antisense oligonucleotide treatment of *ob/ob* mice showed a decrease in weight gain, adipose weight and hepatic TG content. *Id.* In another study, antisense treatment of ob/ob mice improved hepatic steatosis and hyperlipidemia (Yu, *et al.*, *Hepatology*, 2005, 42, 362). Another study showed that diet-induced hepatic steatosis and insulin resistance was improved by knocking down DGAT2 in rats. These effects seem to be unique to inhibition of DGAT2, as ASO against DGAT1 did not lead to similar beneficial effects. Although the molecular mechanism behind these observations remains uncertain, the collective data suggest that suppression of DGAT2 is associated with reduced expression of lipogenic genes (SREBP1c, ACC1, SCD1, and mtGPAT) and increased expression of oxidative/thermogenic genes (CPT1, UCP2) (Choi *et al.*, *J. Bio. Chem.*, 2007, 282, 22678).

[0007] Inhibitors of DGAT2 are useful for treating disease related to the spectrum of metabolic syndrome such as hepatic steatosis, non-alcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

[0008] DGAT2 inhibitor compounds are described in WO2022140169, WO2022076495, WO2022076496, WO2021236401, WO202136405, WO2022050749, WO2021133035, WO2021064590, WO2016036633, WO2016036636, WO2016036638, WO2018093696, WO2018093698, WO2013150416, US20150259323, WO2015077299, WO2017011276, WO2018033832, US201801628, and WO2003053363.

SUMMARY

[0009] The present disclosure is directed to compounds having structural Formula I:



I

or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N and C(R^5);

U is independently selected from N, N(R^3), S and O;

V is independently selected from C(R^4), N, N(R^4) and O;

R^1 is

(1) 6-membered heteroaryl containing 1 or 2 nitrogen atoms,

(2) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1 or 2 nitrogen atoms,

(3) -(C_{1-6})alkyl, or

(4) -(C_{1-4})haloalkyl,

wherein each heteroaryl, alkyl or haloalkyl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is

(1) 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, or

(2) -(C_{3-6})cycloalkyl,

wherein each cycloalkyl or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^7;

when present, each R^3 is selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

(C_{1-6})alkyl-oxetanyl optionally substituted with halogen;

each R^4 is independently selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

(C_{1-3})alkyl-heterocyclyl wherein the heterocyclyl is a 4- to 6-membered heterocyclyl containing 1 oxygen heteroatom, optionally substituted with halogen;

when present, each R^5 is independently selected from

hydrogen,

halogen, or

(C_{1-3})alkyl;

when present, each R^6 is independently selected from

(1) halogen,

(2) (C_{1-6})alkyl,

(3) O-(C_{1-6})haloalkyl, or

(4) (C_{1-6})haloalkyl;

when present, each R^7 is independently selected from

halogen,

oxo,

(C_{1-3})alkyl,


(C_{1-3})haloalkyl,

O(C_{1-3})alkyl,

C(O)(C_{1-3})haloalkyl, or

OH.

[0010] In an example of this disclosure are compounds of Formula I, or a pharmaceutically acceptable salt thereof, is the compound of Formula Ia;



Ia

or pharmaceutically acceptable salts thereof wherein:

X is independently selected from N or C(R^5);

R^1 is a 6-membered heteroaryl containing containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 R^6;

R^2 is a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 R^7;

R^4 is selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

(C_{1-3})alkyl-heterocyclyl wherein the heterocyclyl is a 4- to 6-membered heterocyclyl containing 1 oxygen heteroatom, optionally substituted with halogen;

when present, each R^5 is independently selected from hydrogen, halogen or (C_{1-3})alkyl;

when present, each R^6 is independently selected from

halogen,

(C_{1-6})alkyl,

-(C_{1-6})haloalkyl, or


O-(C_{1-6})haloalkyl;

when present, each R^7 is independently selected from

oxo, or

(C_{1-3})alkyl.

[0011] In an example of this disclosure are compounds of Formula I, or a pharmaceutically acceptable salt thereof, is the compound of Formula Ib;



Ib

or pharmaceutically acceptable salts thereof wherein:

X, Y, and Z are independently selected from N and C(R^5);

R^1 is

6-membered heteroaryl containing 1 or 2 heteroatoms independently selected from N,

-(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 6-membered heteroaryl containing 1 or 2 nitrogen,

-(C_{1-6})alkyl, or

-(C_{1-4})haloalkyl,

wherein each heteroaryl, alkyl or haloalkyl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 R^7;

R^3 is selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

C_{1-6}alkyl-oxetanyl optionally substituted with halogen;

each R^5 is independently selected from

hydrogen,

halogen, or

(C_{1-3})alkyl;

when present, R^6 is independently

halogen,

(C_{1-6})alkyl,

(C_{1-6})haloalkyl, or

O-(C_{1-6})haloalkyl;

when present, R^7 is independently

halogen,

(C_{1-3})alkyl,

oxo, or

OH.

[0012] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 R^6.

[0013] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 substituents independently selected from OCH_2CF_3 or Cl.

[0014] In an example of this disclosure are compounds of Formula I, Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 R^6.

[0015] In an example of this disclosure are compounds of Formula I, Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein $R^1$is a 6-membered heteroaryl containing containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 substituents independently selected from O-(C_{1-6})haloalkyl and halogen.

[0016] In an example of this disclosure are compounds of Formula I, Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a 6-membered heteroaryl containing containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 substituents independently selected from OCH_2CF_3 and Cl.

[0017] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 substituents selected from halogen, (C_{1-6})alkyl and O-(C_{1-6})haloalkyl.

[0018] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 substituents selected from F, Cl, CH_3, OCH_2CF_3, OCH_2CHF_2 and $OCH_2C(CH_3)(F)_2$.

[0019] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is a -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 substituents selected from halogen, (C_{1-6})alkyl and O-(C_{1-6})haloalkyl.

[0020] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the


foregoing, wherein R^1 is -(C_{1-6})alkyl unsubstituted or substituted with 1, 2, or 3 substituents selected from halogen, (C_{1-6})alkyl and O-(C_{1-6})haloalkyl.

[0021] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is -(C_{1-6})alkyl substituted with O-(C_{1-6})haloalkyl.

[0022] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is -(C_{1-4})haloalkyl substituted with O-(C_{1-6})haloalkyl.

[0023] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is $CH_2CH(OCH_2CHF_2)CH_2CH_3$, $CH_2CH(OCH_2C(CH_3)(F)_2)CH_2CH_3$, $CH_2CH(OCHF_2)CH_2CF_3$, $CH_2CH(OCH_2CHF_2)CH_2CF_3$, $CH_2CH(OCH_2CHF_2)CH_2CF_3$, $CH_2CH(OCH_2CHF_2)CF_3$ and $CH_2CH(OCH_2CHF_2)CHF_2$.

[0024] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is



or .

[0025] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is

[0026] a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 substituents selected from oxo C(O)(C_{1-3})haloalkyl, or (C_{1-3})alkyl, or

[0027] a -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 substituents selected from halogen, (C_{1-3})alkyl, (C_{1-3})haloalkyl, O(C_{1-3})alkyl or OH.

[0028] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 R^7.

[0029] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 substituents selected from oxo, C(O)(C_{1-3})haloalkyl or (C_{1-3})alkyl.

[0030] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a 6-membered heterocyclyl containing 1 sulfur heteroatom which is substituted with 3 substituents selected from oxo or (C_{1-3})alkyl.

[0031] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a 6-membered heterocyclyl containing 1 sulfur heteroatom which is substituted with 3 substituents selected from oxo or CH_3.








[0032] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 R^7.

[0033] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 substituents selected from halogen, (C_{1-3})alkyl, (C_{1-3})haloalkyl, O(C_{1-3})alkyl or OH.

[0034] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 substituents selected from halogen, CH_3, CF_3, OCH_3, or OH.

[0035] In an example of this disclosure are compounds of Formula I, or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 R^7.

[0036] In an example of this disclosure are compounds of Formula I, or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is a -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 substituents selected from halogen, (C_{1-3})alkyl, or OH.

[0037] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is , , , , , , , , or .

[0038] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^3 is hydrogen, (C_{1-3})alkyl, (C_{1-3})haloalkyl, or (C_1-6)alkyl-oxetanyl optionally substituted with halogen.

[0039] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^3 is hydrogen, CH_3, CH_2CH_3, CH_2CHF_2, $CH(CH_3)_2$, or CH_2-oxetanyl-F.

[0040] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^4 is hydrogen, (C_{1-3})alkyl, (C_{1-3})haloalkyl, or (C_{1-3})alkyl -oxetanyl optionally substituted with halogen.

[0041] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^4 is H, CH_3, CH_2CHF_2, CH_2-oxetanyl-F, or $CH(CH_3)_2$.

[0042] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^5 is hydrogen, halogen, or (C_{1-3})alkyl.

[0043] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^5 is hydrogen, halogen, or CH_3.

[0044] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^5 is hydrogen, F, Cl, or CH_3.

[0045] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is halogen, (C_{1-6})alkyl, or O-(C_{1-6})haloalkyl.

[0046] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is F, Cl, CH_3, OCH_2CF_3, OCH_2CHF_2,

$OCH_2C(CH_3)(F)_2$, $OCH_2CH(OCH_2CHF_2)CH_2CH_3$, $OCH_2CH(OCH_2C(CH_3)(F)_2)CH_2CH_3$, $OCH_2CH(OCHF_2)CH_2CF_3$, $OCH_2CH(OCH_2CHF_2)CH_2CF_3$, $OCH_2CH(OCH_2CHF_2)CH_2CF_3$, $OCH_2CH(OCH_2CHF_2)CF_3$, or $OCH_2CH(OCH_2CHF_2)CHF_2$.

[0047] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is O-(C_{1-6})haloalkyl or halogen.

[0048] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is OCH_2CF_3, F or Cl.

[0049] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is OCH_2CF_3 or Cl.

[0050] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is halogen, (C_{1-6})alkyl, or O-(C_{1-6})haloalkyl.

[0051] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^6 is F, Cl, CH_3, OCH_2CF_3, OCH_2CHF_2, $OCH_2C(CH_3)(F)_2$, $OCH_2CH(OCH_2CHF_2)CH_2CH_3$, $OCH_2CH(OCH_2C(CH_3)(F)_2)CH_2CH_3$, $OCH_2CH(OCHF_2)CH_2CF_3$, $OCH_2CH(OCH_2CHF_2)CH_2CF_3$, $OCH_2CH(OCH_2CHF_2)CH_2CF_3$, $OCH_2CH(OCH_2CHF_2)CF_3$, or $OCH_2CH(OCH_2CHF_2)CHF_2$.

[0052] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^7 is halogen, oxo, (C_{1-3})alkyl, (C_{1-3})haloalkyl, O(C_{1-3})alkyl, C(O)(C_{1-3})haloalkyl, or OH.

[0053] In an example of this disclosure are compounds of Formula I, Formula Ia or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically

acceptable salt of any of the foregoing, wherein when present, each R^7 is halogen, oxo, CH_3, CF_3, OCH_3, $C(O)CF_3$, or OH.

[0054] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^7 is oxo or (C_{1-3})alkyl.

[0055] In an example of this disclosure are compounds of Formula I or Formula Ia, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^7 is oxo or CH_3.

[0056] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^7 is oxo, (C_{1-3})alkyl, halogen, or OH.

[0057] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^7 is OH, halogen, oxo, or CH_3.

[0058] In an example of this disclosure are compounds of Formula I or Formula Ib, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein when present, each R^7 is OH, F, Cl, oxo, or CH_3.

[0059] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein U is O, V is N, X is C(H), Y is C(H), and Z is C(H), R^1 is 6-membered heteroaryl containing 1 nitrogen heteroatoms substituted with 1 or 2 R^6 and R^2 is -(C_{3-6})cycloalkyl optionally substituted with 1, 2, or 3 R^7.

[0060] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is Cl or OCH_2CF_3.

[0061] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^7 is OH, F, CH_3, OCH_3, $C(O)CF_3$, or CF_3.

[0062] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein U is O, V is N, X is C(H), Y is C(H), Z is C(H) or N, R^1 is 6-membered heteroaryl containing 1 nitrogen heteroatoms substituted with 1 or 2 R^6, and R^2 is 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S optionally substituted with 1, 2, or 3 R^7.

[0063] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^7 is oxo, CH_3, or $C(O)CF_3$.

[0064] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is Cl or OCH_2CF_3.

[0065] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein U is S, V is N, X is C(H) or N, Y is C(H) or N, Z is C(H), R^1 is 6-membered heteroaryl containing 1 nitrogen heteroatoms substituted with 1 or 2 R^6, and R^2 is either a) a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S optionally substituted with 1, 2, or 3 R^7, or b) a -(C_{3-6})cycloalkyl optionally substituted with 1, 2, or 3 R^7.

[0066] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is Cl, OCH_2CHF_2 or OCH_2CF_3,

[0067] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^7 is oxo, OH, halogen, CH_3 or $C(O)CF_3$.

[0068] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is $C(R^5)$, Y is $C(R^5)$, and Z is $C(R^5)$.

[0069] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is N, Y is $C(R^5)$, and Z is $C(R^5)$.

[0070] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is $C(R^5)$, Y is N, and Z is $C(R^5)$.

[0071] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is $C(R^4)$, Y is $C(R^4)$, and Z is N.

[0072] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is N, Y is $C(R^4)$, and Z is N.


[0073] In an example of this disclosure are compounds of Formula I, or as defined herein, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is N, Y is N, and Z is $C(R^4)$.

[0074] In an example of the disclosure, the compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, is:


6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-[(1*S*,2*R*)-3,3-difluoro-2-hydroxy-cyclohexyl]-1,3-benzoxazole-2-carboxamide,
N-(4-methyl-1,1-dioxo-thian-4-yl)-6-[[3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,3-benzoxazole-2-carboxamide,
6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-1,3-benzoxazole-2-carboxamide,
6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-(3,3-difluoro-1-methyl-cyclobutyl)-1,3-benzoxazole-2-carboxamide,

6-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-1,5-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,
6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,5-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,
2-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-9-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)purine-8-carboxamide,
2-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-9-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)purine-8-carboxamide,
6-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*b*]pyrazine-2-carboxamide,
N-(4-Methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-6-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)benzo[*d*]thiazole-2-carboxamide,
N-(3-methyl-1,1-dioxo-thietan-3-yl)-6-[[3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,3-benzothiazole-2-carboxamide,
N-[(3*S*)-tetrahydrofuran-3-yl]-6-[[3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,3-benzothiazole-2-carboxamide,
5-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)thiazolo[5,4-*b*]pyridine-2-carboxamide,
5-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)thiazolo[5,4-*b*]pyridine-2-carboxamide,
5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-*N*-((1*S*,2*R*)-3,3-difluoro-2-hydroxycyclohexyl)thiazolo[5,4-*b*]pyridine-2-carboxamide,
6-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-*N*-(4-methyl-1,1-dioxo-thian-4-yl)thiazolo[4,5-*c*]pyridine-2-carboxamide,
N-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-6-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)oxazolo[4,5-*b*]pyridine-2-carboxamide, or
6-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-pyrrolo[2,3-*b*]pyridine-2-carboxamide.


[0075] In an example, the compound of Formula I, Formula Ia, Formula Ib, or a pharmaceutically acceptable salt thereof, is:




[0076] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is




[0077] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is




[0078] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is




[0079] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is




[0080] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is




[0081] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is




[0082] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is



[0083] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is



[0084] In an example is a compound, or a pharmaceutically acceptable salt thereof, which is



[0085] The present disclosure includes the pharmaceutically acceptable salts of the compounds defined therein.

[0086] In another aspect, the present disclosure includes a composition comprising a pharmaceutically acceptable carrier and a compound as defined herein, or a pharmaceutically acceptable salt thereof. The present disclosure also includes a composition comprising an effective amount of at least one compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof.

[0087] The disclosure also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0088] The disclosure also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent).

[0089] The disclosure also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

[0090] In another aspect, the present disclosure includes a composition for use in treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically carrier. In one example, the present disclosure provides a composition for treating hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases or heart failure comprising an acceptable carrier and a compound of Formula I or Formula Ib, or a pharmaceutically acceptable salt thereof.

[0091] In one example, the present disclosure provides a composition for treating hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases or heart failure, comprising a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof.

[0092] In one example, the present disclosure provides a composition for treating hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases or heart failure, comprising a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0092a] In another aspect, the present disclosure includes a compound as defined herein, or a pharmaceutically acceptable salt thereof, for use in therapy.

[0093] In one example, the present disclosure provides a method of treating hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases or heart failure in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of at least one compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof.

[0094] In one example, the present disclosure provides a method of treating hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases or heart failure in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of at least one compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0095] The methods of the disclosure include the administration of a pharmaceutical composition comprising at least one compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0096] In another example, the present disclosure includes a method of treating NASH and/or fibrosis, comprising administering to a patient in need thereof a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof.




[0097] In another example, the present disclosure includes a method of treating NASH and/or fibrosis, comprising administering to a patient in need thereof a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0098] In another example, the present disclosure includes a method of treating NASH and/or fibrosis, comprising administering to a patient in need thereof a composition comprising a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof.

[0099] In another example, the present disclosure includes a method of treating NASH and/or fibrosis, comprising administering to a patient in need thereof a composition comprising a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0100] In another aspect, the present disclosure includes use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure. In another example, the present disclosure provides for the use of a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating NASH and/or fibrosis.

[0101] In another example, the present disclosure includes the use of a compound of Formula I, Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of NASH and/or fibrosis.

[0102] "**Alkyl**" means branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms when noted. If no number is specified, 1-6 carbon atoms are intended for linear and 3-7 carbon atoms for branched alkyl groups. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, *sec*- and *tert*-butyl, pentyl, hexyl, octyl, nonyl, and the like. For example, the term "$C_{1\text{-}6}$alkyl" includes all of "$C_{1\text{-}4}$alkyl" defined as follows, plus the linear or branched chain alkyl groups, including all possible isomers, having 5 or 6 carbon atoms. "$C_{1\text{-}6}$alkyl" means linear or branched chain alkyl groups, including all possible isomers, having 1, 2, 3, 4, 5 or 6 carbon atoms, and includes each of the alkyl groups within $C_{1\text{-}6}$alkyl including each of the hexyl and pentyl isomers as well as n-, iso-, sec- and tert-butyl (butyl, i-butyl, s-butyl, t-butyl, collectively "C_4alkyl"; Bu = butyl), n- and i-propyl (propyl, i-propyl, collectively "C_3alkyl"; Pr = propyl), ethyl (Et) and methyl (Me). Commonly used abbreviations for alkyl groups are used throughout the specification, e.g., methyl may be represented by conventional abbreviations including "Me" or CH_3 or a symbol that is an extended bond as the terminal group, e.g., , ethyl may be represented by "Et" or CH_2CH_3, propyl may be represented by "Pr" or $CH_2CH_2CH_3$, butyl may be represented by "Bu" or $CH_2CH_2CH_2CH_3$, etc. For example, the structures  and  have equivalent meanings. If no number is specified, 1-6 carbon atoms are intended for linear or branched alkyl groups.

[0103] "**Alkoxy**" refers to an alkyl group linked to oxygen. Examples of alkoxy groups include methoxy, ethoxy, propoxy and the like.


[0104] "**Aryl**" refers to an aromatic monocyclic or multicyclic ring moiety comprising 6 to 14 ring carbon atoms. In one embodiment, an aryl group contains from about 6 to 10 ring carbon atoms. Monocyclic aryl rings include, but are not limited to, phenyl. Multicyclic rings include, but are not limited to, naphthyl and bicyclic rings wherein phenyl is fused to a $C_{5\text{-}7}$cycloalkyl or $C_{5\text{-}7}$cycloalkenyl ring. Aryl groups may be optionally substituted with one or more substituents as defined herein. Bonding can be through any of the carbon atoms of any ring.

[0105] "**Halogen**" or "Halo" includes fluorine, chlorine, bromine and iodine.

[0106] "**Cycloalkyl**" refers to a non-aromatic mono-or multicyclic ring system comprising about 3 to 10 ring carbon atoms. If no number of atoms is specified, 3-10 carbon atoms are

Claims

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N and C(R^5);

U is independently selected from N, N(R^3), S and O;

V is independently selected from C(R^4), N, N(R^4) and O;

R^1 is

(1) 6-membered heteroaryl containing 1 or 2 nitrogen atoms,

(2) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 5- or 6-membered heteroaryl containing 1 or 2 nitrogen atoms,

(3) -(C_{1-6})alkyl, or

(4) -(C_{1-4})haloalkyl,

wherein each heteroaryl, alkyl or haloalkyl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is

(1) 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, or

(2) -(C_{3-6})cycloalkyl,

wherein each cycloalkyl or heterocyclyl is unsubstituted or substituted with 1, 2, or 3 R^7;

when present, each R^3 is selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

(C_{1-6})alkyl-oxetanyl optionally substituted with halogen;

each R^4 is independently selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

(C_{1-3})alkyl-heterocyclyl wherein the heterocyclyl is a 4- to 6-membered heterocyclyl containing 1 oxygen heteroatom, optionally substituted with halogen;

when present, each R^5 is independently selected from

hydrogen,

halogen, or

(C_{1-3})alkyl;

when present, each R^6 is independently selected from

(1) halogen,

(2) (C_{1-6})alkyl,

(3) O-(C_{1-6})haloalkyl, or

(4) (C_{1-6})haloalkyl;

when present, each R^7 is independently selected from

halogen,

oxo,

(C_{1-3})alkyl,


(C_{1-3})haloalkyl,

O(C_{1-3})alkyl,

C(O)(C_{1-3})haloalkyl, or

OH.

2. A compound of claim 1, of Formula Ib,



Ib

or a pharmaceutically acceptable salt thereof wherein:

X, Y, and Z are independently selected from N and C(R^5);

R^1 is

6-membered heteroaryl containing 1 or 2 heteroatoms independently selected from N,

-(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 6-membered heteroaryl containing 1 or 2 nitrogen,

-(C_{1-6})alkyl, or

-(C_{1-4})haloalkyl,

wherein each heteroaryl, alkyl or haloalkyl is unsubstituted or substituted with 1, 2, or 3 R^6;

R^2 is a 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 R^7;

R^3 is selected from

hydrogen,

(C_{1-3})alkyl,

(C_{1-3})haloalkyl, or

C1-6alkyl-oxetanyl optionally substituted with halogen;

each R5 is independently selected from

hydrogen,

halogen, or

(C1-3)alkyl;

when present, R6 is independently

halogen,

(C1-6)alkyl,

(C1-6)haloalkyl, or

O-(C1-6)haloalkyl;

when present, R7 is independently

halogen,

(C_{1-3})alkyl,

oxo, or

OH.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is

(1) 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 $R^{6,}$

(2) -(C_{1-6})alkyl-heteroaryl, wherein the heteroaryl is a 6-membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with 1, 2, or 3 s R^6,

(3) -(C_{1-6})alkyl unsubstituted or substituted with 1, 2, or 3 R^6, or

(4) -(C_{1-4})haloalkyl substituted with 1, 2, or 3 R.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R^2 is

(1) 4- to 7-membered heterocyclyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which is unsubstituted or substituted with 1, 2, or 3 R^7, or

(2) -(C_{3-6})cycloalkyl, which is unsubstituted or substituted with 1, 2, or 3 R^7.

5. The compound of any one of claims 1, 3, or 4, or a pharmaceutically acceptable salt thereof, wherein $R^3$is hydrogen, (C_{1-3})alkyl, (C_{1-3})haloalkyl, or (C_1-6)alkyl-oxetanyl optionally substituted with halogen.

6. The compound of any one of claims 1, 3-5, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, (C_{1-3})alkyl, (C_{1-3})haloalkyl, or (C_{1-3})alkyl -oxetanyl optionally substituted with halogen.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R^5 is hydrogen, halogen, or (C_{1-3})alkyl.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein R^6 is halogen, (C_{1-6})alkyl, or O-(C_{1-6})haloalkyl.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^7 is halogen, oxo, (C_{1-3})alkyl, (C_{1-3})haloalkyl, O(C_{1-3})alkyl, C(O)CF_3, or OH.

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein X is C(R^5), Y is C(R^5), and Z is C(R^5).

11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is C(R^5), and Z is C(R^5).

12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein X is C(R^5), Y is N, and Z is C(R^5).

13. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein X is C(R^4), Y is C(R^4), and Z is N.

14. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is C(R^4), and Z is N.

15. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein X is N, Y is N, and Z is C(R^4).

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-[(1*S*,2*R*)-3,3-difluoro-2-hydroxy-cyclohexyl]-1,3-benzoxazole-2-carboxamide,

N-(4-methyl-1,1-dioxo-thian-4-yl)-6-[[3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-(3,3-difluoro-1-methyl-cyclobutyl)-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-[(3*S*)-tetrahydrofuran-3-yl]-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-[3-methoxy-3-(trifluoromethyl)cyclobutyl]-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-[3-methoxy-3-(trifluoromethyl)cyclobutyl]-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-[1-(2,2,2-trifluoroacetyl)azetidin-3-yl]-1,3-benzoxazole-2-carboxamide,

6-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-*N*-(4,4-difluoro-1-methyl-cyclohexyl)-1,3-benzoxazole-2-carboxamide,

N-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-5-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)benzo[*d*]oxazole-2-carboxamide,

1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-6-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1*H*-benzo[*d*]imidazole-2-carboxamide,

1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-5-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-fluoro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-fluoro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((3-(2,2-difluoroethoxy)-5-fluoropyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((3-(2,2-difluoroethoxy)-5-fluoropyridin-2-yl)oxy)-1-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-7-fluoro-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

5-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-4-fluoro-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

7-chloro-6-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

4-chloro-5-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1,7-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

5-((5-chloro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-1,4-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

6-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-4-fluoro-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-benzo[*d*]imidazole-2-carboxamide,

5-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[5-chloro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoropropoxy)-5-fluoro-2-pyridyl]oxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-3-methyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

3-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-5-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

3-methyl-*N*-(3-methyl-1,1-dioxidothietan-3-yl)-5-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoroethoxy)-5-fluoro-2-pyridyl]oxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoroethoxy)-5-fluoro-2-pyridyl]oxy]-3-methyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoroethoxy)-5-methyl-2-pyridyl]oxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[3-(2,2-difluoroethoxy)pyrazin-2-yl]oxy-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoroethoxy)-5-fluoro-2-pyridyl]oxy]-*N*-[(1*S*,2*R*)-3,3-difluoro-2-hydroxy-cyclohexyl]-3-methyl-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-*N*-[(1*S*,2*R*)-3,3-difluoro-2-hydroxy-cyclohexyl]-3-methyl-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-6-fluoro-3-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

6-fluoro-5-((5-fluoro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-3-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoropropoxy)-5-fluoro-2-pyridyl]oxy]-6-fluoro-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-chloro-5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3,6-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-fluoro-3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)-3,6-dimethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoropropoxy)-5-fluoro-2-pyridyl]oxy]-3,6-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[3-(2,2-difluoroethoxy)-5-fluoro-2-pyridyl]oxy]-3,6-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-3,7-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridin-4-ium-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3-isopropyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-(2,2-difluoroethyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3-(2,2-difluoroethyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3-ethyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-((3-fluorooxetan-3-yl)methyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-3-((3-fluorooxetan-3-yl)methyl)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)methoxy)-3-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-3*H*-imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[[5-Fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]methoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[2-(2,2-Difluoroethoxy)butoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

5-[2-(2,2-Difluoropropoxy)butoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*R*)-5-[2-(difluoromethoxy)-4,4,4-trifluoro-butoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*S*)-5-[2-(difluoromethoxy)-4,4,4-trifluoro-butoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*R*)-5-[2-(2,2-difluoroethoxy)-4,4,4-trifluoro-butoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*S*)-5-[2-(2,2-difluoroethoxy)-4,4,4-trifluoro-butoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*R*)-5-[2-(2,2-difluoroethoxy)-3,3,3-trifluoro-propoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*S*)-5-[2-(2,2-difluoroethoxy)-3,3,3-trifluoro-propoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*R*)-5-[2-(2,2-difluoroethoxy)-3,3-difluoro-propoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

(*S*)-5-[2-(2,2-difluoroethoxy)-3,3-difluoro-propoxy]-3-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-chloro-3-(2,2-difluoropropoxy)-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)-6-[3-(2,2,2-trifluoroethoxy)pyrazin-2-yl]oxy-imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-1-methyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[3-(2,2-difluoroethoxy)-5-fluoro-2-pyridyl]oxy]-1-methyl-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[3-(2,2-difluoroethoxy)-5-fluoro-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[3-(2,2-difluoroethoxy)-5-methyl-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[5-chloro-3-(2,2-difluoroethoxy)pyridin-1-ium-2-yl]oxy-1,4-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-*N*-[(1*S*,2*R*)-3,3-difluoro-2-hydroxy-cyclohexyl]-1-methyl-imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-7-fluoro-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

7-fluoro-6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-1,7-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,7-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)methoxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-Fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]methoxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*c*]pyridine-2-carboxamide,

6-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-1,7-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,7-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-1,5-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

6-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,5-dimethyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)imidazo[4,5-*b*]pyridine-2-carboxamide,

2-[[5-Chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-9-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)purine-8-carboxamide,

2-[[5-fluoro-3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-9-methyl-*N*-(4-methyl-1,1-dioxo-thian-4-yl)purine-8-carboxamide,

6-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-imidazo[4,5-*b*]pyrazine-2-carboxamide,

N-(4-Methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-6-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)benzo[*d*]thiazole-2-carboxamide,

N-(3-methyl-1,1-dioxo-thietan-3-yl)-6-[[3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,3-benzothiazole-2-carboxamide,

N-[(3*S*)-tetrahydrofuran-3-yl]-6-[[3-(2,2,2-trifluoroethoxy)-2-pyridyl]oxy]-1,3-benzothiazole-2-carboxamide,

5-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)thiazolo[5,4-*b*]pyridine-2-carboxamide,

5-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-*N*-(3-methyl-1,1-dioxo-thietan-3-yl)thiazolo[5,4-*b*]pyridine-2-carboxamide,


5-((5-chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-*N*-((1*S*,2*R*)-3,3-difluoro-2-hydroxycyclohexyl)thiazolo[5,4-*b*]pyridine-2-carboxamide,


6-[[5-chloro-3-(2,2-difluoroethoxy)-2-pyridyl]oxy]-*N*-(4-methyl-1,1-dioxo-thian-4-yl)thiazolo[4,5-*c*]pyridine-2-carboxamide,


N-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-6-((3-(2,2,2-trifluoroethoxy)pyridin-2-yl)oxy)oxazolo[4,5-*b*]pyridine-2-carboxamide, or


6-((5-Chloro-3-(2,2-difluoroethoxy)pyridin-2-yl)oxy)-1-methyl-*N*-(4-methyl-1,1-dioxidotetrahydro-2*H*-thiopyran-4-yl)-1*H*-pyrrolo[2,3-*b*]pyridine-2-carboxamide.


17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:



































18. A composition for use in treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising a compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically carrier.

19. A composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof.

20. A compound of any of claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use in therapy.

21. Use of a compound of any of claims 1 to 17, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure.